Applied Clinical Trials-12-01-2022

Regulations that apply across geographic borders can provide researchers and patients a firmer foundation on data protection.

A roadmap to avoiding the common pitfalls of concurrent FDA-EMA filings.

Summarizing important FDA and EMA revisions issued this year.

Navigating FDA’s draft guidance and heightened diversity recommendations.

Final presentation at DIA reminds: "we are all patients."

Study indentifies trends in most commonly used KRIs.

Nabil Chehab, medical affairs head of lung cancer franchise at AstraZeneca, discuss strategies used in the Phase III AEGEAN trial for treating non-small lung cancer (NSCLC).

Debates caught between focusing on existing antibiotics and developing new agents.

Looking back on major FDA moves in 2022.

Industry straddling two worlds as new year approaches.

Click the title above for a link to open the Applied Clinical Trials December 2022 issue in an interactive PDF format.

Why oncology needs dosing redesign.